Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): From bench to clinic

Mutation Research - Reviews in Mutation Research

Volumn 728, Issue 1-2, 2011, Pages 47-66

  Banerjee, Sanjeev ^a   Kong, Dejuan ^a   Wang, Zhiwei ^a   Bao, Bin ^a   Hillman, Gilda G ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3,3' Diindolylmethane; Brassica sps; Prevention; Therapy

Indexed keywords

3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; 3,3' DIINDOLYLMETHANE DERIVATIVE; 5,5' DIBROMO 3,3' DIINDOLYLMETHANE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; BRCA1 PROTEIN; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B1; DOCETAXEL; ESTROGEN RECEPTOR; GAMMA INTERFERON; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN C JUN; PROTEIN KINASE B; SURVIVIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; WNT PROTEIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIZATION; COLON CANCER; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG URINE LEVEL; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; METASTASIS INHIBITION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; UTERINE CERVIX CARCINOMA IN SITU;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL AVAILABILITY; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH;

BRASSICA; BRASSICA OLERACEA VAR. BOTRYTIS; BRASSICA OLERACEA VAR. CAPITATA; BRASSICA OLERACEA VAR. GEMMIFERA; BRASSICA OLERACEA VAR. ITALICA;

EID: 79961211147     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2011.06.001     Document Type: Review

References (144)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Reed G.A., Arneson D.W., Putnam W.C., Smith H.J., Gray J.C., Sullivan D.K., Mayo M.S., Crowell J.A., Hurwitz A. Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2477-2481.
3. Reed G.A., Sunega J.M., Sullivan D.K., Gray J.C., Mayo M.S., Crowell J.A., Hurwitz A. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiol. Biomarkers Prev. 2008, 17:2619-2624.
4. Crowell J.A., Page J.G., Levine B.S., Tomlinson M.J., Hebert C.D. Indole-3-carbinol, but not its major digestive product 3,3'-diindolylmethane, induces reversible hepatocyte hypertrophy and cytochromes P450. Toxicol. Appl. Pharmacol. 2006, 211:115-123.
5. Morse M.A, Stoner G.D. Cancer chemoprevention: principles and prospects. Carcinogenesis 1993, 14:1737-1746.
6. Wattenberg L.W. Chemoprevention of cancer. Cancer Res. 1985, 45:1-8.
7. Tsuchiya Y., Nakajima M., Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005, 227:115-124.
8. Lake B.G., Tredger J.M., Renwick A.B., Barton P.T., Price R.J. 3,3'-Diindolylmethane induces CYP1A2 in cultured precision-cut human liver slices. Xenobiotica 1998, 28:803-811.
9. Stresser D.M., Bjeldanes L.F., Bailey G.S., Williams D.E. The anticarcinogen 3,3'-diindolylmethane is an inhibitor of cytochrome P-450. J. Biochem. Toxicol. 1995, 10:191-201.
10. Gross-Steinmeyer K., Stapleton P.L., Liu F., Tracy J.H., Bammler T.K., Quigley S.D., Farin F.M., Buhler D.R., Safe S.H., Strom S.C., Eaton D.L. Phytochemical-induced changes in gene expression of carcinogen-metabolizing enzymes in cultured human primary hepatocytes. Xenobiotica 2004, 34:619-632.
11. Gross-Steinmeyer K., Stapleton P.L., Tracy J.H., Bammler T.K., Strom S.C., Buhler D.R., Eaton D.L. Modulation of aflatoxin B1-mediated genotoxicity in primary cultures of human hepatocytes by diindolylmethane, curcumin, and xanthohumols. Toxicol. Sci. 2009, 112:303-310.
12. Parkin D.R, Malejka-Giganti D. Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3'-diindolylmethane and its parent compound indole-3-carbinol. Cancer Detect. Prev. 2004, 28:72-79.
13. Parkin D.R., Lu Y., Bliss R.L., Malejka-Giganti D. Inhibitory effects of a dietary phytochemical 3,3'-diindolylmethane on the phenobarbital-induced hepatic CYP mRNA expression and CYP-catalyzed reactions in female rats. Food Chem. Toxicol. 2008, 46:2451-2458.
14. Jellinck P.H., Makin H.L., Sepkovic D.W., Bradlow H.L. Influence of indole carbinols and growth hormone on the metabolism of 4-androstenedione by rat liver microsomes. J. Steroid Biochem. Mol. Biol. 1993, 46:791-798.
15. Vivar O.I., Saunier E.F., Leitman D.C., Firestone G.L., Bjeldanes L.F. Selective activation of estrogen receptor-{beta} target genes by 3,3'-diindolylmethane. Endocrinology 2010, 151:1662-1667.
16. Li Y., Li X., Sarkar F.H. Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J. Nutr. 2003, 133:1011-1019.
17. Bonnesen C., Eggleston I.M., Hayes J.D. Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines. Cancer Res. 2001, 61:6120-6130.
18. Wortelboer H.M., de Kruif C.A., van Iersel A.A., Falke H.E., Noordhoek J., Blaauboer B.J. Acid reaction products of indole-3-carbinol and their effects on cytochrome P450 and phase II enzymes in rat and monkey hepatocytes. Biochem. Pharmacol. 1992, 43:1439-1447.
19. Choi H.J., Lim d.Y., Park J.H. Induction of G1 and G2/M cell cycle arrests by the dietary compound 3,3'-diindolylmethane in HT-29 human colon cancer cells. BMC Gastroenterol. 2009, 9:39.
20. Tadi K., Chang Y., Ashok B.T., Chen Y., Moscatello A., Schaefer S.D., Schantz S.P., Policastro A.J., Geliebter J., Tiwari R.K. 3,3'-Diindolylmethane, a cruciferous vegetable derived synthetic anti-proliferative compound in thyroid disease. Biochem. Biophys. Res. Commun. 2005, 337:1019-1025.
21. Chang X., Firestone G.L., Bjeldanes L.F. Inhibition of growth factor-induced Ras signaling in vascular endothelial cells and angiogenesis by 3,3'-diindolylmethane. Carcinogenesis 2006, 27:541-550.
22. Chang X., Tou J.C., Hong C., Kim H.A., Riby J.E., Firestone G.L., Bjeldanes L.F. 3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice. Carcinogenesis 2005, 26:771-778.
23. Gong Y., Sohn H., Xue L., Firestone G.L., Bjeldanes L.F. 3,3'-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res. 2006, 66:4880-4887.
24. Hong C., Kim H.A., Firestone G.L., Bjeldanes L.F. 3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression. Carcinogenesis 2002, 23:1297-1305.
25. Gartel A.L., Serfas M.S., Tyner A.L. p21--negative regulator of the cell cycle. Proc. Soc. Exp. Biol. Med. 1996, 213:138-149.
26. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 2000, 60:3689-3695.
27. Vivar O.I., Lin C.L., Firestone G.L., Bjeldanes L.F. 3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status. Biochem. Pharmacol. 2009, 78:469-476.
28. Chinnakannu K., Chen D., Li Y., Wang Z., Dou Q.P., Reddy G.P., Sarkar F.H. Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J. Cell. Physiol. 2009, 219:94-99.
29. Garikapaty V.P., Ashok B.T., Tadi K., Mittelman A., Tiwari R.K. 3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. Biochem. Biophys. Res. Commun. 2006, 340:718-725.
30. Rajoria S., Suriano R., Wilson Y.L., Schantz S.P., Moscatello A., Geliebter J., Tiwari R.K. 3,3'-Diindolylmethane inhibits migration and invasion of human cancer cells through combined suppression of ERK and AKT pathways. Oncol. Rep. 2011, 25:491-497.
31. Jin Y., Zou X., Feng X. 3,3'-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells. Anticancer Drugs 2010, 21:814-822.
32. Kandala P.K., Srivastava S.K. Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol. Pharmacol. 2010, 78:297-309.
33. Fan S., Meng Q., Saha T., Sarkar F.H., Rosen E.M. Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res. 2009, 69:6083-6091.
34. Bae I., Fan S., Meng Q., Rih J.K., Kim H.J., Kang H.J., Xu J., Goldberg I.D., Jaiswal A.K., Rosen E.M. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res. 2004, 64:7893-7909.
35. Gopalakrishnan A., Tony Kong A.N. Anticarcinogenesis by dietary phytochemicals: cytoprotection by Nrf2 in normal cells and cytotoxicity by modulation of transcription factors NF-kappa B and AP-1 in abnormal cancer cells. Food Chem. Toxicol. 2008, 46:1257-1270.
36. Kelner M.J., Bagnell R.D., Montoya M.A., Estes L.A., Forsberg L., Morgenstern R. Structural organization of the microsomal glutathione S-transferase gene (MGST1) on chromosome 12p13.1-13.2. Identification of the correct promoter region and demonstration of transcriptional regulation in response to oxidative stress. J. Biol. Chem. 2000, 275:13000-13006.
37. Anderton M.J., Manson M.M., Verschoyle R., Gescher A., Steward W.P., Williams M.L., Mager D.E. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab. Dispos. 2004, 32:632-638.
38. Gudmundsdottir K., Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25:5864-5874.
39. Sun S., Han J., Ralph W.M., Chandrasekaran A., Liu K., Auborn K.J., Carter T.H. Endoplasmic reticulum stress as a correlate of cytotoxicity in human tumor cells exposed to diindolylmethane in vitro. Cell Stress Chaperones 2004, 9:76-87.
40. Abdelrahim M., Newman K., Vanderlaag K., Samudio I., Safe S. 3,3'-Diindolylmethane (DIM) and its derivatives induce apoptosis in pancreatic cancer cells through endoplasmic reticulum stress-dependent upregulation of DR5. Carcinogenesis 2006, 27:717-728.
41. Savino J.A., Evans J.F., Rabinowitz D., Auborn K.J., Carter T.H. Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane. Mol. Cancer Ther. 2006, 5:556-563.
42. Cheng J.S, Shu S.S., Kuo C.C., Chou C.T., Tsai W.L., Fang Y.C., Kuo L.N., Yeh J.H., Chen W.C., Chien J.M., Lu T., Pan C.C., Cheng H.H., Chai K.L., Jan C.R. Effect of diindolylmethane on Ca(2+) movement and viability in HA59T human hepatoma cells. Arch. Toxicol. 2011.
43. Cano E., Mahadevan L.C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 1995, 20:117-122.
44. Juge N., Mithen R.F., Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell. Mol. Life Sci. 2007, 64:1105-1127.
45. Chen Y.R., Wang X., Templeton D., Davis R.J., Tan T.H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem. 1996, 271:31929-31936.
46. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
47. Xue L., Firestone G.L., Bjeldanes L.F. DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 2005, 24:2343-2353.
48. Choi K.H., Kim H.K., Kim J.H., Choi E.S., Shin J.A., Lee S.O., Chintharlapalli S., Safe S., Abdelrahim M., Kong G., Choi H.S., Jung J.Y., Cho H.T., Cho N.P., Cho S.D. The p38 MAPK pathway is critical for 5,5'-dibromodiindolylmethane-induced apoptosis to prevent oral squamous carcinoma cells. Eur. J. Cancer Prev. 2010, 19:153-159.
49. Khwaja F.S., Wynne S., Posey I., Djakiew D. 3,3'-Diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Cancer Prev. Res. (Phila Pa) 2009, 2:566-571.
50. Kelly W.K., O'Connor O.A., Marks P.A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs 2002, 11:1695-1713.
51. Kelly W.K., Richon V.M., O'Connor O., Curley T., Gregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9:3578-3588.
52. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., Gregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23:3923-3931.
53. Huang X., Guo B. Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res. 2006, 66:9245-9251.
54. Bhatnagar N., Li X., Chen Y., Zhou X., Garrett S.H., Guo B. 3,3'-Diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin. Cancer Prev. Res. (Phila Pa) 2009, 2:581-589.
55. Li Y., Li X., Guo B. Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res. 2010, 70:646-654.
56. Eisenberg-Lerner A., Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis 2009, 14:376-391.
57. Chen D.Z., Qi M., Auborn K.J., Carter T.H. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J. Nutr. 2001, 131:3294-3302.
58. Li Y., Chinni S.R., Sarkar F.H. Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front. Biosci. 2005, 10:236-243.
59. Banerjee S., Wang Z., Kong D., Sarkar F.H. 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res. 2009, 69:5592-5600.
60. Kim E.J., Shin M., Park H., Hong J.E., Shin H.K., Kim J., Kwon D.Y., Park J.H. Oral administration of 3,3'-diindolylmethane inhibits lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice. J. Nutr. 2009, 139:2373-2379.
61. Ahmad A., Kong D., Wang Z., Sarkar S.H., Banerjee S., Sarkar F.H. Down-regulation of uPA and uPAR by 3,3'-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cells. J. Cell. Biochem. 2009, 108:916-925.
62. Rahman K.W., Sarkar F.H. Inhibition of nuclear translocation of nuclear factor-{kappa}B contributes to 3,3'-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res. 2005, 65:364-371.
63. Rahman K.W., Li Y., Wang Z., Sarkar S.H., Sarkar F.H. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res. 2006, 66:4952-4960.
64. Maciejewska D., Rasztawicka M., Wolska I., Anuszewska E., Gruber B. Novel 3,3'-diindolylmethane derivatives: synthesis and cytotoxicity, structural characterization in solid state. Eur. J. Med. Chem. 2009, 44:4136-4147.
65. Ali S., Banerjee S., Ahmad A., El-Rayes B.F., Philip P.A., Sarkar F.H. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol. Cancer Ther. 2008, 7:1708-1719.
66. Gong Y., Firestone G.L., Bjeldanes L.F. 3,3'-diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells. Mol. Pharmacol. 2006, 69:1320-1327.
67. Contractor R., Samudio I.J., Estrov Z., Harris D., McCubrey J.A., Safe S.H., Andreeff M., Konopleva M. A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Res. 2005, 65:2890-2898.
68. Ichite N., Chougule M.B., Jackson T., Fulzele S.V., Safe S., Singh M. Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin. Cancer Res. 2009, 15:543-552.
69. Nachshon-Kedmi M., Yannai S., Haj A., Fares F.A. Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. Food Chem. Toxicol. 2003, 41:745-752.
70. Nachshon-Kedmi M., Yannai S., Fares F.A. Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3'-diindolylmethane through the mitochondrial pathway. Br. J. Cancer 2004, 91:1358-1363.
71. Ge X., Yannai S., Rennert G., Gruener N., Fares F.A. 3,3'-Diindolylmethane induces apoptosis in human cancer cells. Biochem. Biophys. Res. Commun. 1996, 228:153-158.
72. Wang Z., Yu B.W., Rahman K.M., Ahmad F., Sarkar F.H. Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip. Mol. Cancer Ther. 2008, 7:341-349.
73. Hong C., Firestone G.L., Bjeldanes L.F. Bcl-2 family-mediated apoptotic effects of 3,3'-diindolylmethane (DIM) in human breast cancer cells. Biochem. Pharmacol. 2002, 63:1085-1097.
74. Moiseeva E.P., Almeida G.M., Jones G.D., Manson M.M. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol. Cancer Ther. 2007, 6:3071-3079.
75. Kim E.J, Park S.Y., Shin H.K., Kwon D.Y., Surh Y.J., Park J.H. Activation of caspase-8 contributes to 3,3'-diindolylmethane-induced apoptosis in colon cancer cells. J. Nutr. 2007, 137:31-36.
76. Azmi A.S., Ahmad A., Banerjee S., Rangnekar V.M., Mohammad R.M., Sarkar F.H. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm. Res. 2008, 25:2117-2124.
77. Lee S.H., Kim J.S., Yamaguchi K., Eling T.E., Baek S.J. Indole-3-carbinol and 3,3'-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem. Biophys. Res. Commun. 2005, 328:63-69.
78. Roy A., Ganguly A., BoseDasgupta S., Das B.B., Pal C., Jaisankar P., Majumder H.K. Mitochondria-dependent reactive oxygen species-mediated programmed cell death induced by 3,3'-diindolylmethane through inhibition of F0F1-ATP synthase in unicellular protozoan parasite Leishmania donovani. Mol. Pharmacol. 2008, 74:1292-1307.
79. Rahman K.M., Banerjee S., Ali S., Ahmad A., Wang Z., Kong D., Sakr W.A. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. Cancer Res. 2009, 69:4468-4475.
80. Rahman K.M., Ali S., Aboukameel A., Sarkar S.H., Wang Z., Philip P.A., Sakr W.A., Raz A. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol. Cancer Ther. 2007, 6:2757-2765.
81. Ali S., Varghese L., Pereira L., Tulunay-Ugur O.E., Kucuk O., Carey T.E., Wolf G.T., Sarkar F.H. Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett. 2009, 278:201-209.
82. Hankinson O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 1995, 35:307-340.
83. Perdew G.H. Association of the Ah receptor with the 90-kDa heat shock protein. J. Biol. Chem. 1988, 263:13802-13805.
84. Kazlauskas A., Sundstrom S., Poellinger L., Pongratz I. The hsp90 chaperone complex regulates intracellular localization of the dioxin receptor. Mol. Cell. Biol. 2001, 21:2594-2607.
85. Carver L.A., Bradfield C.A. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J. Biol. Chem. 1997, 272:11452-11456.
86. Denison M.S., Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43:309-334.
87. Nebert D.W., Roe A.L., Dieter M.Z., Solis W.A., Yang Y., Dalton T.P. Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis. Biochem. Pharmacol. 2000, 59:65-85.
88. Whitlock J.P Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 1999, 39:103-125.
89. Degner S.C., Papoutsis A.J., Selmin O., Romagnolo D.F. Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3'-diindolylmethane in breast cancer cells. J. Nutr. 2009, 139:26-32.
90. Hestermann E.V., Brown M. Agonist and chemopreventative ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol. Cell. Biol. 2003, 23:7920-7925.
91. Jellinck P.H., Forkert P.G., Riddick D.S., Okey A.B., Michnovicz J.J., Bradlow H.L. Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochem. Pharmacol. 1993, 45:1129-1136.
92. McDougal A., Gupta M.S., Morrow D., Ramamoorthy K., Lee J.E., Safe S.H. Methyl-substituted diindolylmethanes as inhibitors of estrogen-induced growth of T47D cells and mammary tumors in rats. Breast Cancer Res. Treat. 2001, 66:147-157.
93. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002, 62:5196-5203.
94. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
95. Shin I., Yakes F.M., Rojo F., Shin N.Y., Bakin A.V., Baselga J., Arteaga C.L. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 2002, 8:1145-1152.
96. Scott P.H., Brunn G.J., Kohn A.D., Roth R.A., Lawrence J.C. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7772-7777.
97. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
98. Kucab J.E., Lee C., Chen C.S., Zhu J., Gilks C.B., Cheang M., Huntsman D., Yorida E., Emerman J., Pollak M., Dunn S.E. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 2005, 7:R796-R807.
99. Bhuiyan M.M, Li Y., Banerjee S., Ahmed F., Wang Z., Ali S., Sarkar F.H. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res. 2006, 66:10064-10072.
100. Chen Y., Xu J., Jhala N., Pawar P., Zhu Z.B., Ma L., Byon C.H., McDonald J.M. Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein. Am. J. Pathol. 2006, 169:1833-1842.
101. Kong D., Li Y., Wang Z., Banerjee S., Sarkar F.H. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res. 2007, 67:3310-3319.
102. Kong D., Banerjee S., Huang W., Li Y., Wang Z., Kim H.R., Sarkar F.H. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-d-overexpressing PC3 cells. Cancer Res. 2008, 68:1927-1934.
103. Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006, 5:671-688.
104. Li Y., Wang Z., Kong D., Murthy S., Dou Q.P., Sheng S., Reddy G.P., Sarkar F.H. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J. Biol. Chem. 2007, 282:21542-21550.
105. Narayanan R., Yepuru M., Szafran A.T., Szwarc M., Bohl C.E., Young N.L., Miller D.D., Mancini M.A., Dalton J.T. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res. 2010, 70:842-851.
106. Mulvey L., Chandrasekaran A., Liu K., Lombardi S., Wang X.P., Auborn K.J., Goodwin L. Interplay of genes regulated by estrogen and diindolylmethane in breast cancer cell lines. Mol. Med. 2007, 13:69-78.
107. Carter T.H., Liu K., Ralph W., Chen D., Qi M., Fan S., Yuan F., Rosen E.M., Auborn K.J. Diindolylmethane alters gene expression in human keratinocytes in vitro. J. Nutr. 2002, 132:3314-3324.
108. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
109. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302:1-12.
110. Casalini P., Iorio M.V. MicroRNAs and future therapeutic applications in cancer. J. BUON 2009, 14(Suppl. 1):S17-S22.
111. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 2009, 27:5848-5856.
112. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., Menard S., Palazzo J.P., Rosenberg A., Musiani P., Volinia S., Nenci I., Calin G.A., Querzoli P., Negrini M., Croce C.M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
113. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
114. Kunimasa K., Kobayashi T., Kaji K., Ohta T. Antiangiogenic effects of indole-3-carbinol and 3,3'-diindolylmethane are associated with their differential regulation of ERK1/2 and Akt in tube-forming HUVEC. J. Nutr. 2010, 140:1-6.
115. Riby J.E., Firestone G.L., Bjeldanes L.F. 3,3'-Diindolylmethane reduces levels of HIF-1alpha and HIF-1 activity in hypoxic cultured human cancer cells. Biochem. Pharmacol. 2008, 75:1858-1867.
116. Ahmad A., Kong D., Sarkar S.H., Wang Z., Banerjee S., Sarkar F.H. Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J. Cell. Biochem. 2009, 107:516-527.
117. Rajoria S., Suriano R., George A., Shanmugam A., Schantz S.P., Geliebter J., Tiwari R.K. Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer. PLoS ONE 2011, 6:e15879.
118. Rahimi M., Huang K.L., Tang C.K. 3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Lett. 2010, 295:59-68.
119. Dong L., Xia S., Gao F., Zhang D., Chen J., Zhang J. 3,3'-Diindolylmethane attenuates experimental arthritis and osteoclastogenesis. Biochem. Pharmacol. 2010, 79:715-721.
120. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
121. Ali S., Banerjee S., Schaffert J.M., El-Rayes B.F., Philip P.A., Sarkar F.H. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J. Cell. Biochem. 2010.
122. McGuire K.P., Ngoubilly N., Neavyn M., Lanza-Jacoby S. 3,3'-Diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J. Surg. Res. 2006, 132:208-213.
123. Ahmad A., Ali S., Wang Z., Ali A.S., Sethi S., Sakr W.A., Raz A., Rahman K.W. 3, 3'-Diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through down-regulation of FoxM1. Int. J. Cancer 2010.
124. Zhang S., Shen H.M., Ong C.N. Down-regulation of c-FLIP contributes to the sensitization effect of 3,3'-diindolylmethane on TRAIL-induced apoptosis in cancer cells. Mol. Cancer Ther. 2005, 4:1972-1981.
125. Pappa G., Strathmann J., Lowinger M., Bartsch H., Gerhauser C. Quantitative combination effects between sulforaphane and 3,3'-diindolylmethane on proliferation of human colon cancer cells in vitro. Carcinogenesis 2007, 28:1471-1477.
126. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
127. Jacobs I.C., Zeligs M.A. Facilitated absorption of a hydrophobic dietary ingredient. Proc. Int. Symp. Control. Rel. Bioact. Mater. 1999, 26:958-959.
128. Jacobs I.C., Zeligs M.A. New formulation strategies for bioavailability enhancement of two poorly absorbed phytonutrient supplements: diindolylmethane and yohimbine bark extract. Proc. Int. Symp. Control. Rel. Bioact. Mater. 2000, 27:1324-1325.
129. Nestorov I. Whole body pharmacokinetic models. Clin. Pharmacokinet. 2003, 42:883-908.
130. Sepkovic D.W., Bradlow H.L., Bell M. Quantitative determination of 3,3'-diindolylmethane in urine of individuals receiving indole-3-carbinol. Nutr. Cancer 2001, 41:57-63.
131. Chen I., McDougal A., Wang F., Safe S. Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998, 19:1631-1639.
132. Nachshon-Kedmi M., Fares F.A., Yannai S. Therapeutic activity of 3,3'-diindolylmethane on prostate cancer in an in vivo model. Prostate 2004, 61:153-160.
133. Cho H.J., Park S.Y., Kim E.J., Kim J.K., Park J.H. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. Mol. Carcinog. 2011, 50:100-112.
134. Sepkovic D.W., Stein J., Carlisle A.D., Ksieski H.B., Auborn K., Bradlow H.L. Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2957-2964.
135. Sepkovic D.W, Stein J., Carlisle A.D., Ksieski H.B., Auborn K., Raucci L., Nyirenda T., Bradlow H.L. Results from a dose response study using 3, 3'-diindolylmethane in the K14-HPV16 transgenic mouse model: cervical histology. Cancer Prev. Res. (Phila) 2011.
136. Cho S.D., Lei P., Abdelrahim M., Yoon K., Liu S., Guo J., Papineni S., Chintharlapalli S., Safe S. 1,1-bis(3'-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells. Mol. Carcinog. 2008, 47:252-263.
137. Cho S.D., Chintharlapalli S., Abdelrahim M., Papineni S., Liu S., Guo J., Lei P., Abudayyeh A., Safe S. 5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells. Mol. Cancer Ther. 2008, 7:2109-2120.
138. Lee S.O., Li X., Khan S., Safe S. Targeting NR4A1 (TR3) in cancer cells and tumors. Expert Opin. Ther. Targets 2011, 15:195-206.
139. Yoon K., Lee S.O., Cho S.D., Kim K., Khan S., Safe S. Activation of nuclear TR3 (Nr4a1) by a diindolylmethane analog induces apoptosis and proapoptotic genes in pancreatic cancer cells and tumors. Carcinogenesis 2011.
140. Dalessandri K.M., Firestone G.L., Fitch M.D., Bradlow H.L., Bjeldanes L.F. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr. Cancer 2004, 50:161-167.
141. Sanderson J.T., Slobbe L., Lansbergen G.W., Safe S., van den B.M. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and diindolylmethanes differentially induce cytochrome P450 1A1, 1B1, and 19 in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 2001, 61:40-48.
142. Heath E.I., Heilbrun lk, Vaishampayan U.N., Li J., Harper F., Zeligs M., Pemberton P., Sarkar F.H. A phase-I dose escalation study of oral BR-DIM (BioResponse 3,3'-diindolylmethane) in castrate-resistant, non-metastatic, PSA relapse prostate cancer patients. ASCO Meeting Genitourinary Cancer Symposium 2009.
143. Del P.G, Gudipudi D.K., Montemarano N., Restivo A.M., Malanowska-Stega J., Arslan A.A. Oral diindolylmethane (DIM): Pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol. Oncol. 2010, 116:464-467.
144. Auborn K.J. Therapy for recurrent respiratory papillomatosis. Antivir. Ther. 2002, 7:1-9.